Apple stock reacts to new iPhones with a 'meh'

Genuine smart watch and iPhone innovations were unveiled at Apple’s Special Event, but nothing groundbreaking, so the shares fell.


Genuine smart watch and iPhone innovations were unveiled at Apple’s Special Event, but they were deemed by investors to be merely iterative, so the shares fell.

Watch steals the show

Surprises were lacking. Almost all product leaks proved accurate though Watch upgrades stole the show. Apple is pushing deeper into cardiology, elderly and possibly palliative care with impressive features that enable users to take their own cardiogram, detect irregular heartbeats, and have alerts sent if they fall. The wearable medical device market may have a CAGR of 18% between 2015-2023 according to research published by Transparency Market Research in May. Yet at $10bn, it will remain relatively small by the end of the forecast period. These innovations therefore have an eye to the very long view in healthcare. With annual Watch revenues running at $6bn compared with Apple's total 2017 revenues of £229bn, the effort has not been wasted, but it isn’t the main focus.

New iPhones dull (almost) to the Max

On the surface, iPhone upgrades were perhaps the dullest, right down to the term ‘Max’ added to the new top-end model. In order of price, size, and to an extent capability, from lowest to highest, the new line-up is iPhone Xr (initially priced at $749) X and XS (both at $999), with XS Max priced at $1099. Xr is a new category. The other handsets take spots previously held by X, 8 Plus and 8S. Ironically, Xr offers rare hardware innovations. It is one of the most advanced smartphones utilising an LCD display. LCD components are on average cheaper vs. LED, so presumably, Xr was less expensive to produce, allowing Apple to pack it with features previously found at the higher end.

Processor power

Deep within their DNA, the new handsets all sport genuine feature innovations, enabled by new A12 bionic chips. For one, users can now edit depth of field effects in photos, a feature not available on any other top end handset. Such introductions, whilst subtle, probably mean iPhones can retain their ability to delight the hand, eye and to an extent, the mind of devotees, ensuring minimal drift to different platforms, whilst continuing to attract new users.

Perspicacious pricing

One key takeaway from the tweaked X range is nuanced pricing. Top-tier iPhone XS Max looks cheaper than expected. A $200 bump was widely foreseen for the zenith handset after iPhone X initially retailed at $999. With Apple’s highly prized gross profit margin in sharp focus ahead of Wednesday’s event, investors would have seized on any move to ‘give away’ proven demand inelasticity. As it stands, the stock fell after Apple's biggest ‘Special Event’ of the year, but pricing wasn’t the reason. In fact, two mid-tier iPhone Xs now occupying the previous top price point ensure the new range won’t tax quarterly gross margins at all.

On with the show

In short, little was announced at the Steve Jobs Theater on Wednesday that could blow anyone’s socks off, whilst the lack of material upgrades for Apple's fading Mac and iPad lines was a key missed opportunity. But Apple did no damage to handset revenue prospects. After a brief attempt to retake this week’s highs, Apple shares closed 1.2% lower. They even returned to the red well before CEO Tim Cook and co-presenters wrapped up. Still, with a rise of 30% this year, Apple stock has surpassed a host of high-beta technology leaders, notably achieving the $1 trillion-dollar milestone even as trade disputes intensified. The group faces questions about how it will navigate supply chain and demand risks if the U.S. and China continue to face off. But Apple keeps the edge over rivals in consumer hardware.


Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.